Two papers by Professor Shomura of the Faculty of Nursing have been accepted. One analyzed the effect of atezolizumab and bevacizumab combination therapy for hepatocellular carcinoma from the perspective of patients' Health-Related Quality of Life (HRQOL) , and revealed that HRQOL is an important factor that also affects prognosis.
Shomura M, Okabe H, Sakakibara M, Sato E, Shiraishi K, Arase Y, Tsuruya K, Mishima Y, Hirose S, Kagawa T. Impact of Atezolizumab + Bevacizumab Therapy on Health-Related Quality of Life in Patients with Advanced Hepatocellular Carcinoma . Cancers (Basel). 2024 Oct 25;16(21):3610. doi: 10.3390/cancers16213610.PMID: 39518049
The other paper is a compilation of surveys of major facilities nationwide on the extent to which team medical care is being carried out to detect irAEs, side effects of immune checkpoint inhibitors, early on. It is an important report for understanding the current status of irAE response teams in Japan.
Immune-related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan. Hepatol Res. 2024 Nov 30. doi: 10.1111/hepr.14144. Online ahead of print. PMID: 39614809
Comments